Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Online Software Designed to Enhance Target Enrichment Custom Design Process for Next-Generation Sequencing

By BiotechDaily International staff writers
Posted on 04 Jul 2013
A new next-generation sequencing online software’s design algorithm provides an empirically optimized probe database that allows users to obtain and review designs in an automated setting before making the purchase decision.

Roche (Basel, Switzerland) announced the worldwide launch of the NimbleDesign tool, an online software that enables customers to easily design optimized SeqCap EZ Choice Libraries in as little as one hour.

“NimbleDesign is based on years of target enrichment design experience from our bioinformatics experts,” said Thomas Schinecker, president of Roche sequencing solutions. “Following the very positive feedback we received from pilot users in selected regions we are excited to offer this software tool globally now. It marks another step in our ongoing efforts to improve the customer convenience of our target enrichment portfolio.”

The NimbleDesign application enables customers to take full use of Roche’s novel SeqCap EZ library technology, providing more effective finding of single nucleotide polymorphisms (SNPs) and better uniform coverage than many other existing technologies. Furthermore, using the easy-to-use interface, users can develop multiple designs simultaneously with very fast turnaround time. Adding to the customer convenience with the launch of SeqCap EZ reagents earlier in 2013, the NimbleDesign tool additionally streamlines the design workflow and ordering process.

The system is developed for life science research only.

Related Links:
Roche



Channels

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.